Opthea Doses First Patient in Ph2A for OPT-302 in Wet AMD
Filed with ASX · · 3 pages · English
Story so far
Earlier from Opthea
- Opthea Ph1 wAMD Trial with OPT-302 Meets Primary Objective
- Circadian Capital Raising Prospectus
- Opthea Completes Patient Enrolment for Phase 1 wet AMD Trial
- Half Year Report and Accounts
- Circadian Receives $3M R&D Tax Incentive
Later from Opthea
- Opthea reports positive data from Phase 1 wet AMD Trial
- Appendix 4E and Annual Report 2016
- Opthea receives $2.6M R&D tax incentive
- Opthea Completes Patient Enrolment in Ph1/2A wAMD Trial
- Opthea Completes FDA Meeting to Inform OPT-302 Program
Follow Opthea into a list and get an email when it puts out news.
Follow Opthea